Wednesday, January 25, 2012 — SYMPOSIA DAY

Full Day Symposia

9:00AM-5:00PM

A Manage Macromolecule Challenges to Deliver a Robust Biologic Product

B Maximize the Potential of Your Drug Delivery System Through Drug Delivery Device Combination Products

C Implementing and Maintaining a Specialty Pharma Business Model to Sustain Your Drug Delivery Units

1/2 Day Symposia

9:00AM-12:30PM

I Maximize Opportunities for Your Product by Developing for Special Populations: Pediatrics and Geriatrics

II Understand the Payer Perspective and Adjust Your Strategies Accordingly to Ensure Reimbursement of Your
Drug Delivery Product

1:30PM-5:00PM

III Nanotechnology and RNAi Use for Drug Formulation and Delivery: How Do We Move Closer to Success?

5:00 Grand Opening Reception and Casino Night in the DDP Hall

Thursday, January 26, 2012 — Main Conference Day One

Registration and Breakfast

Chairperson Kick-Off
Lee Shorter, Director, Platform Technology and Science Open Innovation, GLAXOSMITHKLINE

KEYNOTE:
Adapt to the New Rules for Profitability— The New Role of Drug Delivery in the Changing Drug
Development Paradigm

John Baldoni, Senior Vice President, Platform Technology & Science, GLAXOSMITHKLINE

KEYNOTE:
Will it Help or Hurt? The Impact of Healthcare Reform on Drug Delivery Innovation, Reimbursement, and Patient Compliance
Mark McClellan, Director, ENGLEBERG CENTER FOR HEALTHCARE REFORM, BROOKINGS INSTITUTE, Former Commissioner, US FDA, Former Administrator, CENTERS FOR MEDICARE AND MEDICAID SERVICES

New Drug Delivery Technologies Enable Intradermal Delivery of Biologics:3M Drug Delivery Systems
Mark Tomai, PhD, Head, TRL and MTS Business Development, 3M DRUG DELIVERY SYSTEMS

Networking Break in the Drug Delivery Partnerships Hall

TRACK A

TRACK B

TRACK C

TRACK D

The New Partnering Landscape: Using Co-Development, Novel IP Strategies and Emerging Markets for Growth & Sustainability

Make Life Cycle Management and Risk Sharing Work for More Effective Commercialization

Incorporate Formulation into the Delivery Strategy for Optimal Partnering Opportunities

Novel Drug Delivery Technology and Partnering Case Studies

The Partnering Paradox:
Balance the Need to Partner in Early Stage Development with the Desire to Minimize Risk

Julia Rashba-Step, Sr. Director, Novel Delivery Technologies, Biotherapeutics R&D, PFIZER

Anand Subramony, PhD, Principal Fellow & Head, Novel Delivery Technologies & Therapeutics (NDT), NOVARTIS

Michael Flakus, Director, WW Business Development, PFIZER

Improve the Current
Molecule and Delivery Systems as an Alternative to the NCE to Find Faster and Easier Success

David Cipolla, Director, Pharmaceutical Sciences, Aradigm Corporation

Preformulation is the New
Formulation: Work with Discovery Teams to Determine Formulation and Delivery Strategies

Michael Kaufman, VP, Formulation Science, MILLENIUM PHARMACEUTICALS Dr.

Brian Winger, Director, Preformulation, ELI LILLY

Dr. Geoffrey Hird, Principal Scientist, Formulation & Drug Delivery Technologies, EISAI

Gain a Foothold in Emerging Markets: Where to go and How to get there?

Susan Koppy, Sr. VP, Business Development, ASLAN PHARMACEUTICALS

Harvinder Popli, PhD, Director and Head In-Licensing, RANBAXY LABS, LTD

Robert J. Bloder, Vice President, Business Development, AVEVA DRUG DELIVERY SYSTEMS, INC.

Implement Innovative Drug Development Strategies to Overcome the Cost Hurdle and Reduce Risk

Debra Bingham, Partner, VALEO Partners

Keith Horspool, VP, Pharmaceutics, BOEHRINGER INGELHEIM

Biosimilars: Opportunity
or Threat?

Samuele Butera, VP & Head, Biopharmaceuticals North America, SANDOZ, INC.

Peter Wickersham, SVP, Cost of Care, PRIME THERAPEUTICS

Bill Martin, Group VP, Business Development, Accredo Health

Lunch

Take on the 505b2 Monster and Develop an Optimized Strategy to Ensure Regulatory Approval

Danchen Gao, Director of lP Strategy, Pharmaceutical Products Group, ABBOTT LABORATORIES

Jeffrey A. Wolfson, Partner, HAYNES & BOONE, LLP

Convenience vs. Complaince: Understanding the Current Standards for Reimbursement

John Liu, Senior Director, Reimbursement Strategy, ASTELLAS PHARMA

Strategic Role of Drug Delivery in Biologic Life Cycle

Dr. Jack Kelley, VP, Strategic Marketing, UNILIFE

Auto-injector Innovations in Medical Devices

Lior Shtram, Director, Technology Management, FLEXTRONICS MEDICAL

FIRESIDE CHAT:
Walk Down Wall Street—Analyze the Economy's Effects on Pharma and Drug Delivery and Predict Future Trends Moderator: David Steinberg Managing Director, Equity Research, Specialty Pharmaceuticals & Drug Delivery,
DEUTSCHE BANK
Alex Zisson, Partner, Thomas McNerney & Partners
Brett Zbar, Partner, Aisling Capital
Scott Henry, CFA, Head, Healthcare Research, Senior Research Analyst, Roth Capital Partners

Pantec Biosolutions Presents: The "P.L.E.A.S.E.® Professional"
Sven Rohmann, MD, PhD, CBO, PANTEC BIOSOLUTIONS

Networking Break in the Drug Delivery Partnerships Hall

KEYNOTE:
The Globalization of the Pharmaceutical and Biotechnology Industry: What Does it Mean for Your
Bottom Line?
G. Steven Burrill, CEO, BURRILL & COMPANY

Featured Panel Discussion: Emerging Markets: What are the Current Market Opportunities and How Do We Make them Profitable?
Moderator: Chris Jones, VP and Global Head, Pharmaceutical Development, ASTRAZENECA

G. Steven Burrill, CEO, BURRILL & COMPANY
Christopher Seaton, SVP, Global Licensing, BAYER PHARMACEUTICALS
Uros Urleb, CSO,SANDOZ

Reception in the Drug Delivery Partnerships Hall

Friday, January 27, 2012 - Main Conference Day Two

Morning Coffee in the DDP Expo Hall

Chairperson Recap of Day One
Sesha Neervannan, Vice President, Pharmaceutical Development, ALLERGAN

KEYNOTE:
See a Need and Fill it: Innovative Ways to Uncover the Next Best Technology

Marc Koska, Inventor and Award Winning Humanitarian

Recent Advances in Oral Disintegrating Tablets and Bi-Layer Tablets Technologies for Better Treatments: Catalent Pharma Solutions

Karen McGregor, R&D Platform Director, CATALENT PHARMA SOLUTIONS

TRACK A

TRACK B

TRACK C

TRACK D

The New Partnering Landscape: Using Co-Development, Novel IP Strategies and Emerging Markets for Growth & Sustainability

Make Life Cycle Management and Risk Sharing Work for More Effective Commercialization

Incorporate Formulation into the Delivery Strategy for Optimal Partnering Opportunities

Novel Drug Delivery Technology and Partnering Case Studies

CASE STUDY: Manage the IP from Early Stage to Commercial

David Azad, Managing Director, GALEN PARTNERS

Robert Jones, CEO,
ACURA PHARMACEUTICALS

Chris Halliday, Partner,
MORGAN LEWIS

Overcome the Adoption
Hurdle to Develop a Product that Will Enjoy Robust Patient Compliance

Riccardo Panicucci, Global Head, Chemical and Pharmaceutical Profiling, NOVARTIS

John Turanin, VP and GM,  ZOGENIX TECHNOLOGIES

Atul Patel, Director, R&D,  Self Administration Injection System, BECTON DICKENSON

Debate: Where is the Money? Large vs. Small Molecules

Mahesh Chaubal, Sr. Director, Drug Development, Medical Products, BAXTER HEALTHCARE

Rajneesh Taneja, Director, Pharmaceutical Development, TAKEDA PHARMACEUTICALS NORTH AMERICA

Weiguo Dai, Research Fellow, Drug Delivery & Device Development, JOHNSON & JOHNSON

MicroCor®: Transdermal
Delivery of Any Size Molecule Using Biodegradable Microstructures

Bobby Singh, PhD, VP, Research & Development, CORIUM INTERNATIONAL

Networking Break in the Drug Delivery Partnerships Hall

The New IP Landscape: Less is More

Philip C. Strassburger, VP and Intellectual Property Counsel, PURDUE PHARMA L.P.

Determine the Pharmacoeconomics of Product Value Enhancement

Ronald L. Smith, PhD, Executive Director and Head, Product Value Enhancement, MERCK

Use Animal Health Divisions to Advance Delivery Technologies

Susan Cady, Director, Formulation Development MERIAL LTD.

Brigitte Cron-Eckhardt, Manager, Drug Delivery, NOVARTIS ANIMAL HEALTH

Advantages of Injectable Sustained Release with DepoFoam

Jay Schrier, Senior Director, Pharmaceutical Development, PACIRA PHARMACEUTICALS

Capitalize on Novel Drug Delivery to Build OTC Brand Franchises

Bob Nissen, Former VP, Business Development & Licensing, Novartis Consumer Health, and New Technologies, Bayer Healthcare, Currently President, NISSEN CONSULTING

David Nelson, CSO, CHATTEM, INC., a Sanofi Company

Case Study: Regional Preferences for Drug Delivery Methodologies in Emerging Markets

Determine the Value in Developing Slow Vs. Rapid Injections

Robin Hwang, Principal, ICP CONSULTING, former VP, Head, Drug Delivery, HALOZYME

On the Rise Showcase

Tim Patrick, President & CEO, CARTICEPT

Andy Rensink, President & COO, TAPEMARK

Jonathan Rigby, President and CEO, STEADYMED

Dan Palmer, PhD, CSO, Q-CHIP LTD

Drug Delivery Technology Company C-Suite Panel
Moderators:
Lee Shorter, Director, Platform Technology and Science Open Innovation, GLAXOSMITHKLINE
Sesha Neervannan, Vice President, Pharmaceutical Development, ALLERGAN

James Ingebrand, General Manager and Vice President, 3M DRUG DELIVERY SYSTEMS
John J. Masiz, Esq, President and CEO,BIOCHEMICS

Close of Conference - See You at the 17th Annual Drug Delivery Partnerships!